Global race for better MDS treatment: can new drug combo extend lives?
NCT ID NCT06641414
Summary
This large, late-stage trial is testing if adding a new drug called lisaftoclax to the standard treatment (azacitidine) helps people with newly diagnosed high-risk MDS live longer. About 490 participants worldwide will be randomly assigned to receive either the new combination or the standard treatment plus a placebo. The main goal is to see if the new combination improves overall survival compared to the current standard.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGHER-RISK MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.